Sitravatinib clinical trials
Also written MGCD516 and BGB-9468.
How each study uses sitravatinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the sitravatinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
35 studies that test it; most in 2021 (10)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 10 |
| 2022 | 8 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 19 · Other 16
Mirati Therapeutics Inc. (12) · BeiGene (6) · Fudan University (2) · M.D. Anderson Cancer Center (2) · Seoul National University Hospital (1) · Zhejiang Cancer Hospital (1) · BeOne Medicines (1) · Grupo Español Multidisciplinar de Melanoma (1)
Often tested with
Tested in the same studies.
Tislelizumab (12) · Docetaxel (2) · Pamiparib (1) · Hpk1 Inhibitor BGB-15025 (1) · Zanidatamab (1) · AZD4547 (1) · Vistusertib (1) · Palbociclib (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses sitravatinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 35
- A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative ResectionRecruitingPhase 2Anhui Provincial HospitalNCT05407519Written as Tislelizumab + SitravatinibHow we know
- Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung CancerTerminatedPhase 3Mirati Therapeutics Inc.NCT03906071Written as SitravatinibHow we know
- A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)Active, not recruitingPhase 2Fudan UniversityNCT04734262Written as SitravatinibHow we know
- Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent StudyCompletedPhase 2/3Mirati Therapeutics Inc.NCT04887870Written as SitravatinibHow we know
- Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesCompletedPhase 3BeOne MedicinesNCT04164199Written as SitravatinibHow we know
- Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.CompletedPhase 2Grupo Español Multidisciplinar de MelanomaNCT05542342Written as SitravatinibHow we know
- National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung CancerCompletedPhase 2University of BirminghamNCT02664935Written as SitravatinibHow we know
- Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell CancerTerminatedPhase 2M.D. Anderson Cancer CenterNCT04904302Written as SitravatinibHow we know
- Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerTerminatedPhase 3BeiGeneNCT04921358Written as SitravatinibHow we know
- Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell CarcinomaTerminatedPhase 2BeiGeneNCT05461794Written as SitravatinibHow we know
- Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLCTerminatedPhase 2Sarah GoldbergNCT04925986Written as SitravatinibHow we know
- Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney CancerCompletedPhase 1/2M.D. Anderson Cancer CenterNCT03015740Written as SitravatinibHow we know
- A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid TumorsCompletedPhase 1BeiGeneNCT03666143Written as SitravatinibHow we know
- A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedPhase 1/2BeiGeneNCT03941873Written as SitravatinibHow we know
- Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy AdultsCompletedPhase 1BeiGeneNCT04472650Written as SitravatinibHow we know
- Sitravatinib in Metastatic Breast CancerTerminatedPhase 2Xiang ZhangNCT04123704Written as SitravatinibHow we know
- Sitravatinib in Advanced Liposarcoma and Other Soft Tissue SarcomasCompletedPhase 2Columbia UniversityNCT02978859Written as MGCD516How we know
- Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid MalignanciesCompletedPhase 1Mirati Therapeutics Inc.NCT04518046Written as SitravatinibHow we know
- PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.CompletedPhase 1Mirati Therapeutics Inc.NCT05255276Written as Sitravatinib 50 mgHow we know
- PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of SubstratesCompletedPhase 1Mirati Therapeutics Inc.NCT04887194Written as SitravatinibHow we know
Codes
What other systems call sitravatinib · ClinicalTrials.gg INT000552
- MeSH (NLM) C000611865sitravatinibOne source NLM
- UNII (FDA) CWG62Q1VTBSITRAVATINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27275860sitravatinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C117734SitravatinibOne source FDA
- DrugBank DB15036One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000611865 | sitravatinib | One source NLM |
| UNII (FDA) | CWG62Q1VTB | SITRAVATINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27275860 | sitravatinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C117734 | Sitravatinib | One source FDA |
| DrugBank | DB15036 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.